FDA approves blood test for Alzheimer's diagnosis

The FDA has approved the first blood test to aid in diagnosing Alzheimer's disease, potentially expanding access to early detection and treatment. This new blood test identifies beta-amyloid, a key brain plaque marker for Alzheimer's, and is cleared for use in patients 55 and older experiencing early symptoms. It offers a less invasive and more affordable alternative to previous diagnostic methods. The test's approval could increase the use of drugs that slow Alzheimer's progression and help differentiate the disease from other cognitive issues. More tests are in development, aiming to create a more regulated market.